A
Adastra Pharmaceuticals
Oral multi-kinase inhibitor development for oncology treatments
About Adastra Pharmaceuticals
Adastra Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer. The company was founded in 2005, formerly known as Tragara Pharmaceuticals, and was acquired by Percans Oncology in September 2021. In January 2019, the company changed its name to Adastra Pharmaceuticals and appointed Scott Megaffin as CEO.
Adastra's lead product candidate is zotiraciclib (formerly TG02), an oral, multi-kinase inhibitor designed to treat glioblastoma multiforme (GBM), a type of aggressive brain cancer. Zotiraciclib functions as a potent cyclin-dependent kinase 9 (CDK9) inhibitor that can cross the blood-brain barrier. Its mechanism involves depleting key antiapoptotic proteins like Mcl-1 and Myc, which are crucial for cancer cell survival. The company has conducted clinical trials in collaboration with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC). A Phase 1b clinical trial, completed in early 2021, investigated zotiraciclib in combination with temozolomide (TMZ) for patients with recurrent high-grade gliomas. The trial met its primary endpoint for progression-free survival and demonstrated that zotiraciclib was well-tolerated, showing particular benefit in patients with IDH-mutated tumors. Following these positive results, Adastra had planned a registration-enabling study.
In September 2021, Cothera Bioscience acquired the exclusive worldwide rights to zotiraciclib. This strategic acquisition allows Cothera to continue the development of the drug, building on the clinical data and regulatory groundwork established by Adastra. Before the acquisition, Adastra had raised a total of $87.6M in funding over several rounds from investors including Domain Associates, Morgenthaler Ventures, and Mitsubishi International.
Source: Dealroom company dataAt a glance
- Headquarters
- San Diego, United States
- Sector
- Health
News
Open roles
Adastra Pharmaceuticals in the San Diego ecosystem
The Adastra Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Domain Associates- PIProQuest Investments
- OPOxford Bioscience Partners
- MVMorgenthaler Ventures
RMI Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Adastra Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adastra Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

